Mar 30, 2020 | COVID-19, News and Updates, Resources
This page collects some of the COVID-19-related federal laws, regulations and guidance that is most relevant to Eyman Partners’ clients and friends. Please feel free to reach out to any of our team members to help you navigate these complex policies during this...
Mar 23, 2020 | 340B, News and Updates
In March 2020, the Health Resources and Services Administration published a set of frequently asked questions (FAQs) for 340B stakeholders related to the COVID-19 pandemic. The FAQs address certain flexibilities and exemptions available to covered entities during the...
Jan 30, 2020 | 340B, Litigation, News and Updates
After the Health and Resource Service Administration (HRSA) issued a December Advisory Opinion requiring 340B discounts for drugs dispensed through contract pharmacies, four drug manufacturers—Eli Lilly, AstraZeneca, Sanofi, and Novo Nordisk—have now filed four...
Jan 30, 2020 | Medicaid, News and Updates
On January 30, 2020, CMS released a letter to state Medicaid directors outlining the agency’s block grant initiative titled “Healthy Adult Opportunity.” CMS will allow states to pursue either an aggregate cap or per-capita-cap approach to managing their Medicaid...
Jan 27, 2020 | 340B, News and Updates
On January 27, 2020, the Governmental Accountability Office (GAO) released a report on the Medicaid 340B Drug Discount Program, particularly how the 340B program intersects with the Medicaid Drug Rebate Program. The GAO argued that a lack of transparency and...
Jan 8, 2020 | 340B, News and Updates
On January 8, 2020, the Centers for Medicare and Medicaid (CMS) issued an informational bulletin outlining a series of best practices for states to consider for avoiding duplicate discounts in the 340B program. According to CMS, the guidance is in response to...
